Frontiers In Medicinal Chemistry

Author(s): Lovely Sinha* and Ujjwal Kumar

DOI: 10.2174/9789815165043123100013

Implications of DNA-acting Agents as Anticarcinogenic Potential in Breast Cancer Therapeutics

Pp: 262-280 (19)

Buy Chapters

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Breast cancer is the most prevalent neoplasm diagnosed in women worldwide. There are many factors responsible for breast cancer susceptibility. Mutation in tumor suppressor genes BRCA1 and BRCA2 predispose women to the early onset of breast cancer. The BRCA genes are involved in multiple cellular processes in response to DNA damage, including checkpoint activation, gene transcription, and DNA repair. Several DNA-acting agents act as effective anticancer used for treating cancer disease. Certain groups of chemicals are known to affect specific phases of cell division, such as, Cyclophosphamide is the most potent and successful anticancer agent that acts by alkylating the N-7position of guanine to cause crosslinking of DNA’s double helix, resulting in DNA breaks that interfere with the DNA replication and RNA transcription. This chapter deals with the classification of DNA-acting agents according to their modes of action.

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books